CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 80 enrolled
Drug / intervention
Quadratus Lumborum Block (QLB) +1 moredrug
Likely dose
Quadratus Lumborum Block (QLB) 40 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03408483
NCT03408483Phase 3Completed

Quadratus Lumborum Block Versus Control for Total Hip Arthroplasty

University of Alabama at Birmingham·interventional·Posted Jan 24, 2018·Updated Jun 9, 2021

In Brief

A Phase 3 clinical trial evaluating Quadratus Lumborum Block (QLB) and Standard of Care for Total Hip Arthroplasty. Completed, enrolled 80 participants across 1 site.

Detailed Summary

Peripheral nerve blocks for joint and extremity surgeries have long been proven to provide effective post-operative analgesia. Of these surgeries, total hip arthroplasty (THA) remains one of the most common orthopedic procedures in the United States with approximately 300,000 operations performed annually. At our institution, post-operative analgesia in these patients is primarily provided through parenteral and oral opioid medications. Quadratus lumborum blocks (QLB) have been described and implemented for various surgical procedures including caesarean and laparoscopic ovarian surgery. Recently, there has been increasing interest in the efficacy of quadratus lumborum blocks for THA. Currently, case reports have established a precedent regarding the efficacy of the QLB for THA in providing superior analgesia and decreasing visual analog pain scores (VAS), but randomized trials are still lacking. The goal of this study is to compare pain scores (VAS), opioid consumption, physical therapy scores, and patient and surgeon satisfaction in patients that receive QLB versus no peripheral nerve blockade in patients undergoing THA. The results of this study have the potential to change standard of care for patients undergoing THA.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedJan 24, 2018
Enrollment StartApr 1, 2018
Primary CompletionMay 10, 2019
Study CompletionAug 22, 2020
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 8.4 years ago

Interventions

Quadratus Lumborum Block (QLB)drug

Under ultrasound guidance, the needle will be advanced to the posterior border of the quadratus lumborum muscle. After negative aspiration, a bolus of 40 mL of 0.25% bupivacaine with 1:400,000 epinephrine will be injected in 5 mL aliquots, ensuring proper placement of needle tip and appropriate spread of local anesthetic.

Standard of Caredrug

This is currently the standard of care, no local anesthetic will be injected. Pain will be managed with parenteral and oral medication.